Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review
Duration of oxygen therapy (hours) · infants with bronchiolitis
1 finding from 1 review
Overall survival · People with advanced non‐small cell lung cancer
TG4010 added to chemotherapy showed no clear difference in overall survival compared with chemotherapy alone (low certainty).
1 finding from 1 review
Progression‐free survival · People with advanced non‐small cell lung cancer
TG4010 added to chemotherapy may leads to lower progression‐free survival compared with chemotherapy alone (low certainty).
1 finding from 1 review
Adverse effects: at least one serious adverse event · People with advanced non‐small cell lung cancer
It is very uncertain whether TG4010 added to chemotherapy changes participants with at least one serious adverse event compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Survival rates at 3 years · People with advanced non‐small cell lung cancer
TG4010 added to chemotherapy showed no clear difference in survival rates at 3 years compared with chemotherapy alone (low certainty).
1 finding from 1 review
Survival rates at 5 years · People with advanced non‐small cell lung cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · People with advanced non‐small cell lung cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Time to initiation of first subsequent therapy This outcome was not reported as a time‐to‐event outcome. Instead, authors of the trials reported the number of participants who received subsequent anticancer therapy after discontinuation of trial t... · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy
The intervention may leads to lower time to initiation of first subsequent therapy This outcome was not… (low certainty).
1 finding from 1 review
Duration of phototherapy (hours) · term and preterm neonates with hyperbilirubinaemia
1 finding from 1 review
Rate of decline of serum bilirubin (micromol/L/hr) · term and preterm neonates with hyperbilirubinaemia
Turning position showed no clear difference in rate of fall of serum total bilirubin at 24 hours of starting… compared with supine under phototherapy (low certainty).
1 finding from 1 review
Duration of phototherapy (hours) · newborn infants with unconjugated hyperbilirubinaemia
1 finding from 1 review
Overall survival (OS) · recurrent platinum‐resistant EOC
Chemotherapy with bevacizumab leads to lower overall survival (OS) compared with chemotherapy alone (high certainty).
1 finding from 1 review
Progression‐free survival · recurrent platinum‐resistant EOC
Chemotherapy with bevacizumab probably leads to lower progression‐free survival (PFS) compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Quality of life · recurrent platinum‐resistant EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (grade ≥ 3) · recurrent platinum‐resistant EOC
Chemotherapy with bevacizumab showed no clear difference in any adverse event grade ≥ 3 compared with chemotherapy alone (low certainty).
1 finding from 1 review
Hypertension (grade ≥ 2) · recurrent platinum‐resistant EOC
Chemotherapy with bevacizumab may leads to higher hypertension (grade ≥ 2) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Bowel fistula / perforation (grade ≥ 2) · recurrent platinum‐resistant EOC
Chemotherapy with bevacizumab showed no clear difference in bowel fistula / perforation (grade ≥ 2) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Overall survival · high‐grade glioma
It is very uncertain whether hypofractionated radiotherapy changes overall survival compared with daily conventionally fractionated radiotherapy (very low certainty).
1 finding from 1 review
Adverse effects · high‐grade glioma
1 finding from 1 review